JNJ 40346527

Drug Profile

JNJ 40346527

Alternative Names: JNJ-244; JNJ-40346527; JNJ-527

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 24 May 2013 Johnson & Johnson plans a clinical trial for Crohn's disease (J&J Business Review 2013)
  • 01 Apr 2013 Janssen Research & Development completes a phase I trial in Hodgkin's disease (second-line therapy or greater) in France and Germany (NCT01572519)
  • 04 Feb 2013 Janssen Research & Development completes enrolment in its phase IIa trial for Rheumatoid arthritis in Argentina, Chile, Czech Republic, Hungary, Bulgaria, Poland, Russia, Ukraine, South Korea & Singapore (NCT01597739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top